IE800321L - An antihypercholesteraemic agent, monacolin k - Google Patents
An antihypercholesteraemic agent, monacolin kInfo
- Publication number
- IE800321L IE800321L IE800321A IE32180A IE800321L IE 800321 L IE800321 L IE 800321L IE 800321 A IE800321 A IE 800321A IE 32180 A IE32180 A IE 32180A IE 800321 L IE800321 L IE 800321L
- Authority
- IE
- Ireland
- Prior art keywords
- substance
- monacolin
- acetone
- c24h36o5
- dichloromethane
- Prior art date
Links
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 title abstract 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 6
- 239000000126 substance Substances 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 1
- 241000031003 Monascus ruber Species 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000921 elemental analysis Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000003208 petroleum Substances 0.000 abstract 1
- 239000000741 silica gel Substances 0.000 abstract 1
- 229910002027 silica gel Inorganic materials 0.000 abstract 1
- 238000004809 thin layer chromatography Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
PURPOSE:To produce blood cholesterol lowering drug by cultivating a monacolin K-producing strain of the microoganism Monascus. CONSTITUTION:Monascus ruber No.1005 (FERM-P4822) strain is cultivated, and the produced physiologically active substance monacolin K is isolated. The substance monacolin K is neutral and colorless crystal. The substance has molecular formula C24H36O5(MW=404). The elemental analysis for C24H36O5:C71.56%; H8.85%; O 19.59%. The substance shows a melting point of 157-159 deg.C and an optical rotation of [alpha]D<25>=+307.6(c=1, in methanol). The substance is soluble in alcohol, acetone, ethyl acetate, chloroform and benzene; and insoluble in hexane and petroleum ether. In chromatographic studies, silica gel thin-layer chromatography employing developer consisting of dichloromethane and acetone in a ratio of dichloromethane to acetone of 4:1 shows a single spot of Rf=0.47.
[JP55111790A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54017856A JPS5925599B2 (en) | 1979-02-20 | 1979-02-20 | New physiologically active substance monacolin K and its production method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE800321L true IE800321L (en) | 1980-08-20 |
| IE49743B1 IE49743B1 (en) | 1985-12-11 |
Family
ID=11955290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE321/80A IE49743B1 (en) | 1979-02-20 | 1980-02-19 | Antihypercholesteraemic agent,monacolin k,and its preparation |
Country Status (27)
| Country | Link |
|---|---|
| JP (1) | JPS5925599B2 (en) |
| KR (1) | KR830002801B1 (en) |
| AT (1) | AT373915B (en) |
| AU (1) | AU532626B2 (en) |
| BE (1) | BE881825A (en) |
| CA (1) | CA1129794A (en) |
| CH (1) | CH645890A5 (en) |
| DD (1) | DD154494A5 (en) |
| DE (2) | DE3051175C2 (en) |
| DK (2) | DK149095C (en) |
| ES (1) | ES8103171A1 (en) |
| FI (1) | FI66427C (en) |
| FR (1) | FR2449685B1 (en) |
| GB (1) | GB2046737B (en) |
| HU (1) | HU182069B (en) |
| IE (1) | IE49743B1 (en) |
| IT (1) | IT1175260B (en) |
| MX (1) | MX6314E (en) |
| NL (1) | NL191540C (en) |
| NO (1) | NO153974C (en) |
| NZ (1) | NZ192919A (en) |
| PH (1) | PH15145A (en) |
| PL (1) | PL124304B1 (en) |
| SE (1) | SE453301B (en) |
| SG (1) | SG6784G (en) |
| SU (2) | SU1158048A3 (en) |
| ZA (1) | ZA80962B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55150898A (en) * | 1979-05-11 | 1980-11-25 | Sankyo Co Ltd | Preparation of a new physiologically active substance mb-530b |
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| JPS5621594A (en) * | 1979-07-27 | 1981-02-28 | Sankyo Co Ltd | Mb-530b carboxylic acid metal salt and its preparation |
| PT72394B (en) * | 1980-02-04 | 1982-09-06 | Merck & Co Inc | Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics |
| AU548996B2 (en) * | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
| JPH0692381B2 (en) * | 1980-03-31 | 1994-11-16 | 三共株式会社 | MB-530A derivative |
| JPS56142236A (en) | 1980-04-08 | 1981-11-06 | Sankyo Co Ltd | Ml-236a and mb-530a derivative |
| DK149080C (en) * | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
| JPS5835144A (en) * | 1981-08-27 | 1983-03-01 | Sankyo Co Ltd | Mb-530b derivative and its preparation |
| US4782084A (en) * | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
| US4997848A (en) * | 1987-10-27 | 1991-03-05 | Sankyo Company, Limited | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition |
| CA2062023A1 (en) | 1992-02-10 | 1993-08-11 | Jagroop S. Dahiya | Novel fungal strains and use thereof in antibiotic production |
| WO1993017991A1 (en) * | 1992-03-04 | 1993-09-16 | Fujisawa Pharmaceutical Co., Ltd. | TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS |
| FI932188L (en) | 1992-05-15 | 1993-11-16 | Sankyo Co | OCTAHYDRONAPTHALENOXIME DERIVATIVES FOER INHIBERING AV CHOLESTEROLBIOSYNTESEN, DERAS FRAMSTAELLNING OCH ANVAENDNING |
| HU210867B (en) * | 1992-11-04 | 1995-10-30 | Biogal Gyogyszergyar | Method for extraction and purification of mevinolin from culture medium |
| US6812007B1 (en) * | 1992-11-04 | 2004-11-02 | Keri Vilmos | Process for the isolation and purification of mevinolin |
| SI9300303A (en) * | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| US5409820A (en) * | 1993-08-06 | 1995-04-25 | Apotex, Inc. | Process for the production of lovastatin using Coniothyrium fuckelii |
| US6046022A (en) | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
| US7238348B2 (en) | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
| UA73074C2 (en) | 1998-03-20 | 2005-06-15 | Method of controlled fermentation for production of lovastatin as hydroxy-acid | |
| HUP0300073A3 (en) | 2000-02-24 | 2004-10-28 | Teva Gyogyszergyar Zartkoeruee | Method of purifying a fermentation broth |
| JP2003525935A (en) | 2000-03-03 | 2003-09-02 | ビオガル ジョジセルジャール アール テー． | Method for purifying lovastatin and simvastatin with reduced levels of dimeric impurities |
| KR20010095780A (en) * | 2000-04-12 | 2001-11-07 | 나가오카 마사시 | Embryo monascus |
| IN192861B (en) | 2000-06-30 | 2004-05-22 | Ranbaxy Lab Ltd | |
| ATE356554T1 (en) | 2001-02-09 | 2007-04-15 | Unilever Nv | FOODS CONTAINING SOY PROTEIN AND STATIN |
| KR100379075B1 (en) | 2002-03-07 | 2003-04-08 | Jinis Biopharmaceuticals Co | Method for producing low cholesterol animal food product and food product therefrom |
| KR20020093147A (en) * | 2002-05-30 | 2002-12-13 | 지니스생명공학 주식회사 | Preventive and Dietary Supplement for adult chronic disease |
| KR100710500B1 (en) | 2005-05-18 | 2007-04-24 | 고려대학교 산학협력단 | Method for producing Monacholine Ｋ using red yeast bacteria |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| EP2373609B1 (en) | 2008-12-19 | 2013-10-16 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| RO128803A0 (en) | 2012-10-12 | 2013-09-30 | Ion Gigel Fulga | COMPOSITION FOR TREATMENT OR PREVENTION OF DISLIPIDEMS |
| CN110331151A (en) * | 2019-04-11 | 2019-10-15 | 北京工商大学 | The construction method of purple Monascus mokH gene overexpression bacterial strain |
| CN111297938A (en) * | 2020-03-11 | 2020-06-19 | 北京康立生医药技术开发有限公司 | Method for detecting lovastatin in composition for assisting in reducing blood fat |
| JP2022135089A (en) * | 2021-03-04 | 2022-09-15 | 小林製薬株式会社 | cholesterol lowering agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612114B2 (en) | 1974-06-07 | 1981-03-18 | ||
| JPS55150898A (en) * | 1979-05-11 | 1980-11-25 | Sankyo Co Ltd | Preparation of a new physiologically active substance mb-530b |
| IL60219A (en) * | 1979-06-15 | 1985-05-31 | Merck & Co Inc | Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them |
-
1979
- 1979-02-20 JP JP54017856A patent/JPS5925599B2/en not_active Expired
-
1980
- 1980-02-19 CA CA345,983A patent/CA1129794A/en not_active Expired
- 1980-02-19 IE IE321/80A patent/IE49743B1/en not_active IP Right Cessation
- 1980-02-19 AU AU55673/80A patent/AU532626B2/en not_active Expired
- 1980-02-19 KR KR1019800000654A patent/KR830002801B1/en not_active Expired
- 1980-02-20 PL PL1980222120A patent/PL124304B1/en unknown
- 1980-02-20 DD DD80219159A patent/DD154494A5/en unknown
- 1980-02-20 IT IT67262/80A patent/IT1175260B/en active
- 1980-02-20 FR FR8003662A patent/FR2449685B1/en not_active Expired
- 1980-02-20 SU SU802887300A patent/SU1158048A3/en active
- 1980-02-20 NO NO800451A patent/NO153974C/en unknown
- 1980-02-20 BE BE0/199476A patent/BE881825A/en not_active IP Right Cessation
- 1980-02-20 NL NL8001041A patent/NL191540C/en not_active IP Right Cessation
- 1980-02-20 ZA ZA00800962A patent/ZA80962B/en unknown
- 1980-02-20 FI FI800506A patent/FI66427C/en not_active IP Right Cessation
- 1980-02-20 MX MX808652U patent/MX6314E/en unknown
- 1980-02-20 AT AT0092980A patent/AT373915B/en not_active IP Right Cessation
- 1980-02-20 HU HU80397A patent/HU182069B/en unknown
- 1980-02-20 PH PH23668A patent/PH15145A/en unknown
- 1980-02-20 DE DE3051175A patent/DE3051175C2/de not_active Expired
- 1980-02-20 CH CH136680A patent/CH645890A5/en not_active IP Right Cessation
- 1980-02-20 NZ NZ192919A patent/NZ192919A/en unknown
- 1980-02-20 ES ES488796A patent/ES8103171A1/en not_active Expired
- 1980-02-20 DE DE3006216A patent/DE3006216C2/en not_active Expired
- 1980-02-20 DK DK73080A patent/DK149095C/en not_active IP Right Cessation
- 1980-02-20 SE SE8001339A patent/SE453301B/en not_active IP Right Cessation
- 1980-02-20 GB GB8005748A patent/GB2046737B/en not_active Expired
- 1980-09-12 SU SU802977031A patent/SU969702A1/en active
-
1984
- 1984-01-24 SG SG67/84A patent/SG6784G/en unknown
-
1989
- 1989-01-18 DK DK021889A patent/DK21889A/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE800321L (en) | An antihypercholesteraemic agent, monacolin k | |
| EP0049422B1 (en) | Stable nonaqueous solution of tetracycline salt | |
| CA1046439A (en) | Physiologically active substances from penicillium citrinum | |
| CA1297030C (en) | Treatment of psoriasis, ichthyosis, and acne with manoalide | |
| JPS5632481A (en) | Antibiotic b-41d, its preparation, and acaricide and anthelminthic agent and repellent containing the same as active constituent | |
| Kamo et al. | Anti-inflammatory Lanostane-Type Triterpene Acids from Piptoporus b etulinus | |
| US5459160A (en) | Iridoid derivatives and the use thereof as a drug | |
| SANKAWA et al. | Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives | |
| KR880010131A (en) | Antibiotic vermisporin, preparation method thereof and pharmaceutical composition comprising the same as an active antimicrobial agent | |
| Bravo B et al. | Trypanocidal withanolides and withanolide glycosides from Dunalia brachyacantha | |
| CA1133921A (en) | Physiologically active derivatives of esterastin and production thereof | |
| Wiley et al. | Erythromycin. XII. 1 The Isolation, properties and partial structure of erythromycin C | |
| Teunisson et al. | Isolation and structure of a biologically reduced aflatoxin B1 | |
| HAYASHI et al. | Antiviral Agents of Plant Origin. II.: Antiviral Activity of Scopadulcic Acid B Derivatives | |
| Djerassi et al. | Terpenoids. V. 1 The Isolation of Iresin, a New Sesquiterpene Lactone2 | |
| US5079377A (en) | Novel androst-4-ene-3,17-dione derivatives and method for preparing same | |
| KR880011168A (en) | Process for preparing macrocyclic compound | |
| US4402948A (en) | Steroid glycoside compounds and methods of use | |
| US5244918A (en) | Benzofuran derivative and pharmaceutical comprising the same as active ingredient | |
| Gerber | Phenoxazinones by oxidative dimerization of aminophenols | |
| Handrick et al. | 3'-Hydroxy-and (.+-.)-3', 11-dihydroxy-. DELTA. 9-tetrahydrocannabinol:(THC) biologically active metabolites of. DELTA. 9-tetrahydrocannabinol | |
| FURUKAWA et al. | Isolation and Structure Determination of 4-O-Tigloyl-11, 13-dihydro-autumnolide, a New Sesquiterpene Lactone from North Carolina Helenium autumnale L. | |
| EP0434376A2 (en) | Ivermectin derivative compounds and process for preparing the same | |
| CA1240333A (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
| Arjmand et al. | Separation of amino conjugates of 2, 4-dichlorophenoxyacetic acid by high-pressure liquid chromatography employing ion-pair techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |